Commercialization


  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

    Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.  

    By May 22, 2024
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era

    Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.

    By Alexandra Pecci • May 21, 2024
  • Eli Lilly CEO Dave Ricks Speaks At The Economic Club Of New York
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    As Lilly surges, headwinds against its weight loss drugs are growing

    After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.

    By May 15, 2024
  • An auto-injector of Eli Lilly's metabolic drug Mounjaro is seen on a gray background
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip

    Big Pharma’s most improved drugs: a new generation of blockbusters

    The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.

    By May 14, 2024
  • pharmacy cash register
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 trends impacting drug spend in the U.S.

    Key factors changing how much Americans spend on prescriptions.

    By Kelly Bilodeau • May 13, 2024
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Biosimilars are gaining ground. The IRA could push them even further next year.

    As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

    By May 13, 2024
  • A sign shows the logo of Eli Lilly's Research Laboratories
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown

    The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.

    By May 9, 2024
  • DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    $4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’

    Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.

    By May 2, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    3 patent expirations in 2024 and how companies are pivoting

    As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.

    By April 17, 2024
  • glp-1 injector
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where the GLP-1 weight loss market goes will depend on data

    As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.

    By April 15, 2024
  • Pills, medical products in black paper bag in shopping cart on red background.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Cutting pills. Rationing insulin. How Americans struggle to pay for drugs.

    More than 20% of Americans are forgoing prescription medications due to costs, according to a recent survey.

    By April 9, 2024
  • Syringe
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future

    Biosimilars promise market competition for branded biologics, which in theory could drive down prices. But so far, winning market share has been a struggle.

    By April 9, 2024
  • Bernice Bennett, genealogist
    Image attribution tooltip
    Permission granted by Alnylam
    Image attribution tooltip

    Alnylam turns to genealogy to find rare disease patients through family trees

    A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.

    By March 26, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Who’s getting left behind in the weight loss bonanza?

    As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

    By Kelly Bilodeau • March 25, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Orchard sets out to sell world’s priciest gene therapy

    Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market. 

    By Kristin Jensen • March 20, 2024
  • bottle of Rezdiffra
    Image attribution tooltip
    Courtesy of Madrigal
    Image attribution tooltip

    With historic MASH approval, Madrigal preps for launch and a public offering

    After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.

    By March 20, 2024
  • Bianca Anghelina, CEO, founder, Aily Labs
    Image attribution tooltip
    Permission granted by Aily Labs
    Image attribution tooltip

    Ex-Novartis exec sets out to create ‘Apple of AI’

    Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.

    By Kelly Bilodeau • March 18, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By Jacob Bell • Updated March 8, 2024
  • Thorny issues in pharma
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

    Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

    By Alexandra Pecci • Feb. 26, 2024
  • blue dosing pen for semaglutide
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ozempic for liver disease? Weight loss drugs could have even more to offer

    GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

    By Kelly Bilodeau • Feb. 26, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Ben Fidler • Feb. 23, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • syringe dollar sign shadow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could Novo, Lilly become first trillion-dollar healthcare companies?

    Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

    By Feb. 2, 2024